Loading...

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:27:25

After a busy time in Boston during the Aging Research...

BiotechTV - News ·

2026/10/05

He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out.

en-us

00:20:49

Monte Rosa Therapeutics announced data for MRT-8102,...

BiotechTV - News ·

2026/10/02

CEO Markus Warmuth walks us through the data and provides a broader update on the pipeline progress at Monte Rosa and for the field of degraders and molecular glues more broadly.

en-us

00:07:59

From Basel: TOLREMO Therapeutics is working on cancer...

BiotechTV - News ·

2026/09/29

CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity.

en-us

00:09:23

From Basel: Forty51 Ventures was formed in Basel four...

BiotechTV - News ·

2026/09/28

Co-Founder & Partner Sascha Oliver Bucher describes the firm and investments it has been making, and shares his thoughts on the VC ecosystem in Europe.

en-us

00:13:31

From Basel: With two products on the market with...

BiotechTV - News ·

2026/09/28

CEO David Veitch discusses Cresemba and Zevtera, both of which have momentum in what used to be market with structural barriers to commercial success, but no longer are in most geographies. Plus, a key phase 3 that will read out for Basilea's next mold infection program, fosmanogepix, in 2028.

en-us

00:09:58

Beacon Therapeutics' gene therapy for X-linked...

BiotechTV - News ·

2026/09/21

Chris Hollowood, Founder of Beacon and CEO of Syncona, describes the top line result and its significance. This is the first pivotal trial in X-linked retinitis pigmentosa to achieve its primary endpoint.

en-us

00:14:39

HCW 2026: BlossomHill IPO'd last month to tackle...

BiotechTV - News ·

2026/09/16

She highlights the company's next generation EGFR, which is in the clinic and reported early stage data at World Lung today, and she describes her goal with the company's Pan-KRAS inhibitor, which is still preclinical.

en-us

00:10:50

HCW 2026: As it approaches a BLA filing for its viral...

BiotechTV - News ·

2026/09/16

CEO Paul Peter Tak walks us through how the data has settled, and the steps the company needs to take before officially filing the BLA in Q4. Plus, an update on lung cancer.

en-us

00:08:49

HCW 2026: H.C. Wainwright & Co. Senior Biotech...

BiotechTV - News ·

2026/09/16

He discusses the big year oncology has had, including in the RAS space, and highlights key catalysts he will be watching throughout the remainder of 2026.

en-us

00:09:16

HCW 2026: InflaRx designed izicopan from the start...

BiotechTV - News ·

2026/09/15

Founder & CEO Niels Riedemann describes what he believes was lacking in design for the competitor, avacopan, which has been pulled from the market in many geographies and is currently in contention at FDA, and how izicopan was built to be different. Now InflaRx needs to prove this to investors and regulators of this.

en-us

00:08:34

HCW 2026: GENFIT has developed a blood based test for...

BiotechTV - News ·

2026/09/15

Pascal Prigent describes the test, which can be used both do diagnose patients and to monitor them. On the therapeutics side, he also discusses IQIRVO, which is marketed by Ipsen, and GENFIT's R&D work in oncology and liver failure.

en-us

00:08:07

HCW 2026: Scribe Therapeutics, which represents the...

BiotechTV - News ·

2026/09/15

Co-Founder and CEO Ben Oakes describes the difference between Scribe's approach and the first generation of CRISPR technologies. He then discusses the PCSK9 program, which harnesses epigenetic silencing, and preclinical work on Lp(a) and APOC3.

en-us

00:09:39

HCW 2026: With a $6B valuation, three approved...

BiotechTV - News ·

2026/09/15

CEO Chris Peetz describes the vision for the company, and its acquisition of Bluejay, which will have phase three readouts both this quarter and next. Plus, his explanation of discussions with FDA on volixibat, and more phase 3 data that is scheduled this year on LIVMARLI.

en-us

00:08:57

HCW 2026: With an in-human proof of concept in hand...

BiotechTV - News ·

2026/09/15

CEO Allan Rein describes the proof of concept Prime has achieved with two patients in Chronic Granulomatous Disease, and discusses the companies plans in Wilson's Disease, Alpha-1 Antitrypsin Deficiency, and Cystic Fibrosis.

en-us

00:06:07

HCW 2026: H.C. Wainwright & Co.'s Managing Director...

BiotechTV - News ·

2026/09/15

He discusses the financing dynamics of the biotech market currently, and comments on whether generalist investors are starting to participate in the sector again.

en-us

00:10:17

HCW 26: H.C. Wainwright Senior Biotechnology Analyst...

BiotechTV - News ·

2026/09/14

Based on his analysis, a higher percentage of biotech companies have been trading up on positive data than the previous year. He also discusses going back to the drawing board on cardiovascular targets, in vivo CAR-T programs, and his key catatalysts to watch throughout the rest of the year.

en-us

00:08:06

HCW 26: Ovid Therapeutics CEO Meg Alexander...

BiotechTV - News ·

2026/09/14

OV329, the GABA-AT inhibitor, will have photosensitivity data over the coming months while OV4071, the KCC2, will start a ketamine challenge study by the end of the year that should give visibility to a host of important biomarkers to better understand its profile.

en-us

00:07:01

HCW 2026: H.C. Wainwright & Co.'s Vice Chair and...

BiotechTV - News ·

2026/09/14

He discusses M&A, which he believes can continue, and the IPO market that finally opened up in 2026. Plus, how positive headlines like Moderna & Merck's cancer vaccine have been causing investors to look at the sector.

en-us

00:08:23

HCW 2026: Innate Pharma announced a deal with Sobi...

BiotechTV - News ·

2026/09/14

CEO Jonathan Dickinson explains the rationale for the Sobi deal and what it means for the development of lacutamab. Plus, preparing for the monalizumab readout and why Innate believes its Nectin 4 is well differentiated and compelling.

en-us

00:06:07

HCW 2026: Trevi Therapeutics was founded under the...

BiotechTV - News ·

2026/09/14

Co-Founder & CEO Jennifer Good shares her take on recent clinical disappointments in the chronic cough space and describes how Trevi's therapy, Haduvio, is different. Plus, an overview of the clinical timelines.

en-us

485 results

Similar Podcasts

The Deep Dive Lab: Unraveling Materials Science

Son Hoang

New Books in Political Science

New Books Network

Station 151

Pale Matter | Realm

Beyond the Divide

Koala Moon

StarTalk with Neil deGrasse Tyson

Neil deGrasse Tyson